BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

KAHR Medical And Cobra BioManufacturing (CBF.L) Partner to Develop Trans Signal Converter Protein Production


5/11/2009 1:41:55 PM

Keele, UK and Jerusalem, Israel: 11 May, 2009, Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, and KAHR Medical Ltd., a Hadasit-Bio-Holdings (HBL, TASE: HDST) portfolio company that develops novel drugs for the treatment of autoimmune diseases, announced today a partnership agreement.

Under the terms of the agreement, Cobra will advance KAHR Medical’s Trans Signal Converter Protein (“TSCP”) technology using Cobra’s maxXpress service and recombinant protein production expertise. More specifically, Cobra will develop and manufacture bulk quantities of KAHR’s TSCP proteins for preclinical and future clinical testing. Currently, two recombinant proteins, KAHR-101 and KAHR-102 are being tested in preclinical studies as potential treatments for rheumatoid arthritis (RA) and psoriasis. Cobra has already developed a purification process for KAHR-101 and batches have already been produced for preclinical testing.

Simon Saxby, CEO of Cobra Biomanufacturing Plc said, “We are delighted that KAHR has chosen Cobra to help develop its TSCP technology. Cobra’s maxXpress service and recombinant protein expertise enable it to provide the required tools and solutions necessary for companies looking to start on the road to clinical trials and market supply. Also, Israel has a rapidly expanding biotech industry and we are very pleased to be establishing a very good relationship there.”

Dr. Noam Shani, CEO of KAHR Medical said, “We have been working together with Cobra for about 18 months on KAHR-101 and KAHR-102 and they have done great work developing a production process for KAHR-101. We are looking forward to a long and successful association.”

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES